The Interreg project Codex4SMEs aims at improving healthcare by the enhanced adoption of Personalized Medicine (PM). PM promises to deliver “the right drug, at the right dose, at the right time, to the right patient” with important cost-savings in public healthcare. Companion diagnostics (Cdx) are an indispensable tool for optimum application of PM, but currently only few therapies (1% in DE) are accompanied by Cdx tests. Codex4SMEs will establish a transnational network of nine partners and two sub-partners from seven countries (DE, FR, NL, UK, IE, LU and AT) and will support SMEs along the value chain of Cdx development.
Due to individual patients’ responses, drugs may have low efficacy or even place the patient at risk of serious side-effects. Personalised Medicine (PM) addresses this problem by offering “the right drug, at the right dose, at the right time, to the right patient.” But to properly work, PM requires the right clinical information. Each new drug can be co-developed with a diagnostic test to demonstrate that the drug works safely and effectively for each individual. Companion diagnostics (Cdx) are thus an indispensable part of PM. However, Cdx development takes time and is expensive.
The global Cdx market is expected to grow rapidly: 22.9%/year over 10 years. NWE (North-West Europe) is home to many innovative SMEs that have the potential to exploit this market. They possess the skills, knowledge and experience, but are dispersed and unfocussed entities and often lack financial resources. As a result, European pharma companies often chose to develop Cdx in the US where the regulatory and commercial platform is mature. There is a need to improve SMEs’ innovative capabilities and raise both international competitiveness and the impact of NWE SMEs in this important global market. Codex4SMEs will directly address this challenge. The project will involve as many SMEs as possible through transnational cooperation. It will reduce time to market / development costs, resulting in added value, strengthening the competitiveness of NWE Cdx SMEs and supporting regional Research and Innovation Strategies for Smart Specialisation (RIS3).
Source: BioRegio STERN / YouTube
- Interreg North-West Europe